- Home
- LXEO vs CLPT Comparison
LXEO vs CLPT Comparison
Compare LXEO & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | CLPT |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.9M | 353.5M |
| IPO Year | 2023 | 2009 |
Fundamental Metrics
Financial Performance| Metric | LXEO | CLPT |
|---|---|---|
| Price | $5.86 | $12.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $18.44 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 613.5K | 392.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $654,000.00 | ★ $36,971,000.00 |
| Revenue This Year | N/A | $45.67 |
| Revenue Next Year | N/A | $19.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.78 |
| 52 Week Low | $2.43 | $8.27 |
| 52 Week High | $10.99 | $30.10 |
Technical Indicators
Market Signals| Indicator | LXEO | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 65.65 |
| Support Level | $5.54 | $10.05 |
| Resistance Level | $6.08 | $15.09 |
| Average True Range (ATR) | 0.32 | 0.79 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 23.85 | 91.53 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.